Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle

American Journal of Respiratory Cell and Molecular Biology

Volumn 21, Issue 1, 1999, Pages 77-88

  Fernandes, Darren ^b   Guida, Elizabeth ^b   Koutsoubos, Valentina ^b   Harris, Trudi ^b   Vadiveloo, Peter ^b   Wilson, John W ^b   Stewart, Alastair G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROSTANE DERIVATIVE; CYCLIN D1; DEXAMETHASONE; ENZYME INHIBITOR; FLAVONOID; FLUTICASONE; GLUCOCORTICOID; MAP2K1 PROTEIN, HUMAN; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; THROMBIN;

ARTICLE; BRONCHUS; CELL CULTURE; CELL CYCLE; CELL DIVISION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IC 50; METABOLISM; PHOSPHORYLATION; SMOOTH MUSCLE;

ANDROSTADIENES; BRONCHI; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CELLS, CULTURED; CYCLIN D1; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLAVONOIDS; GLUCOCORTICOIDS; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 1; MIFEPRISTONE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RETINOBLASTOMA PROTEIN; THROMBIN;

EID: 0033161645     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.21.1.3396     Document Type: Article

References (80)

1. Dunnill, M. S., and G. R. Massarella. 1969. A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema. Thorax 24:176-179.
2. Hossain, S., and B. E. Heard. 1970. Hyperplasia of bronchial muscle in chronic bronchitis, J. Pathol. 101:171-181.
3. Ebina, M., T. Takahashi, T. Chiba, and M. Motomiya. 1993. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma: a 3-D morphometric study. Am. Rev. Respir. Dis. 148:720-726.
4. James, A. L., P. D. Pare, and J. C. Hogg. 1989. The mechanics of airway narrowing in asthma, Am. Rev. Respir. Dis. 139:242-246.
5. Pare, P. D., B. R. Wiggs, A. James, J. C. Hogg, and C. Bosken. 1991. The comparative mechanics and morphology of airways in asthma and in ehronic obstrutive pulmonory disease. Am. Rev. Respir. Dis. 143:1189-1193.
6. Jeffery, P. K., A. J. Wardlaw, P. C. Nelson, J. V. Collins, and A. B. Kay. 1989. Bronchial biopsies in asthma: an ullrastructural, quanntitative study and correlation with hyperractivity. Am. Rev. Respir. Dis. 140:1745-1753.
7. Wiggs, B. R., C. Bosken, P. D. Pare, A. James, and J. C. Hogg. 1992. A model of airway narrowing in asthma and in chronic obstructive pulmo nary disease. Am. Rev. Respir. Dis, 145:1251-1258.
8. Lambert, R. K., B. R. Wiggs, K. Kuwano, J. C. Hogg, and P. D. Pare, 1993. Functional significance of increased airway smooth muscle in asthma and COPD, J. Appl. Physiol. 74:2771-2781.
9. Stewart, A. G., P. R. Tomlinson, and J. W. Wilson. 1995. Regulation of airway wall remodelling: prospects for the development of novel anti-asthma Drugs. In: Advances in Pharmacology. J. T. August, M. W. Anders, F. Murad, and J. T. Coyle, editors. Academic Press, San Diego. 209-254.
10. Stewart, A. G., P, R. Tomlinson, and J. Wilson. 1993. Airway wall remodelling in asthma: a novel target for the development of anti-asthma drugs. Trends Pharmacol. Sci. 14:275-279.
11. Shapiro, P. S., J. N. Evans, R. J. Davis, and J. A. Posada. 1996. The seven-transmembrane-spanning receptors for endothelin and thrornbin cause proliferation of airway smooth muscle cells and activation of the extracellular regulated kinase und e-Jun NH2 terminal kinase groups of mitogen-activated protein kinases. J. biol. Chem. 271:5750-5754.
12. Karpova, A. Y., M. K. Abe, J. Li, P. T. Liu. J. M. Rhee, W. L. Kuo, and M. B. Hershenson. 1997. MEKI is required for PDGF-induced ERK activation and DNA synthesis in tracheal myocytes. Am. J. Physiol. 272:L558-L565.
13. Kelleher, M. D., M. K. Abe,T. O. Chao, M. Jain, J. M. Green, J. Solway, M. R. Rosner, and M. B. Hershenson. 1995. Role of MAP kinase activation in bovine tracheal smooth muscle mitogenesis, Am. J. Physiol. 268:L894-L901.
14. Lenormand, P., C. Sardet, G. Pages, G. L'Allemain. A. Brunet, and J. Pouyssegur. 1993. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J. Cell Biol. 122:1079-1088.
15. Mii, S., R. A. Khalil, K. G. Morgan. J. A. Ware, and K. C, Kent. 1996. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am. J. Physiol. 270:H142-H150.
16. Gille, H., M. Kortenjann, O. Thomae, C. Moomaw, C. Slaughter, M. H. Cobb, and P. E. Shaw. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 14:951-962.
17. Lavoie, J. N., G. L'Allemain, A. Brunet, R. Muller, and J. Pouyssegur. 1996. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271:20608-20616.
18. Liu, J, J., J. R. Chao, M. C. Jiang, S. Y. Ng, J. J. Yen, and H. F. Yang-Yen. 1995. Ras transformation results in an elevated level of cyclin D1 and acceleration of GI progression in NIH 3T3 cells. Mol. Cell Biol. 15:3654-3663.
19. Albanese, C., J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, and R. G. Pestell. 1995. Transforming p21ras mutants and e-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270: 23589-23597.
20. Roussel, M. F., A. M. Theodoras, M. Pagano, and C. J, Sherr. 1995. Rescue of defective mitogenic signaling by D-type eyelins. Proc. Natl. Acad. Sci. USA 92:6837-6841.
21. Lukas, J., J. Bartkova, and J. Bartek. 1996. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRh-controlled GI checkpoint, Mol. Cell Biol. 16:6917-6925.
22. Lahti, J. M., H, Li, and V. J. Kidd. 1997. Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1. J. Biol. Chem. 272:10859-10869.
23. Xiong, W., R. G. Pestell, G. Watanabe, J. Li, M. R. Rosner, and M. B. Hershenson, 1997. Cyclin D1 is required for S phase traversat in bovine tracheal myocytes. Am. J. Physiol. 272:L1205-L1210.
24. Chen, P. L., P. Scully, J. Y. Shew, J. Y. Wang, and W. H. Lee. 1989. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58:1193-1198.
25. Kato, J., H. Matsushime, S. W. Hiebert, M. E. Ewen, and C. J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D dependent kinase CDK4. Genes Dev. 7:331-342.
26. Dowdy, S. F., P. W. Hinds, K. Louie, S. I. Reed, A. Arnold, and R. A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins, Cell 73:499-511.
27. Haahtela,T., M. Jarvinen, T. Kava, K. Kirivanta, S. Koskinen. K. Lehtonen, K. Nikander, T. Persson, O. Selroos, A. Sovijarvi, B. Stenius-Aarniala, T. Svahn, R. Taminivara, and L. Laitinen. 1994. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N. Engl. J. Med. 331:700-705.
28. Barnes, P. J., and I. Adcock. 1993. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. 14:436-441.
29. Schleimer, R. P. 1997. Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. Am. Rev. Respir. Dis. 141 (Suppl.):859-869.
30. Barnes, P. J. 1990. Effect corticosteroids on airway hyperresponsiveness. Am. Rev. Respir. Dis. 141(Suppl.):870-876.
31. Schramm, C. M., G. J. Omlor, L. M. Quinn, and J. P. Noveral. 1996. Methylprednisolone and isoproterenol inhibit airway smooth muscle proliferation by separate and additive mechanisms. Life Sci. 59:PL9-PL14.
32. Young, P. G., S. J. Skinner, and P. N. Black. 1995. Effects of glucocorticoids and beta-adrenoceptor agonists on the proliferation of airway smooth muscle. Eur. J. Pharmacol. 273:137-143.
33. Stewart, A. G., D. Fernandes, and P. R. Tomlinson. 1995. The effect of glucocorticoids on proliferation of human cultured airway smooth muscle. Br. J. Pharmacol. 116:3219-3226.
34. Hansson, A., K. Hehenberger, and M. Thoren. 1996. Long-term treatment of Swiss 3T3 fibroblasts with dexamcthasone attenuates MAP kinase activation induced by insulin-like growth factor-I (IGF-I). Cell Biochem. Funct. 14:121-129.
35. Rider, L. G., N. Hirasawa, F. Santini, and M. A. Beaven, 1996. Activation of the mitogen-aetivated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J. Immunol. 157:2374-2380.
36. King, A. P., and C. Carter-Su. 1995. Dexamethasone-induced antagonism of growth hormone (GH) action by down-regulation of GH binding in 3T3-F442A fibroblasts. Endocrinology 136:4796-4803.
37. Ramalingam, A., A. Hirai, and F. A. Thompson. 1997. Glucocorticoid inhibition of fibroblast proliferation and regulation of the cyclin dependent kinase inhibitor p21Cipl. Mol. Endocrinol. 11:577-586.
38. Corroyer, S., E. Naheyrat, and A. Clement, 1997. Involvement of the cell cycle inhibitor CIPI/WAFI in lung alveolar epithelial cell growth arrest induced by glucocorticoids. Endocrinology 138:3677-3685.
39. Goya, L., A, C. Maiyar, Y. Ge and G. L. Firestone. 1993. Glucocorticoids induce a Gl/GO cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol. Endocrinol. 7:1121-1132.
40. Krontiris. T. G. 1995. Oncogenes. N. Engl. J. Med. 333:303-306.
41. Rhee, K., D. Reisman, W. Bresnahan, and E. A. Thompson. 1995. Glucocorticoid regulation of Gl cyclin-dependent kinase genes in lymphoid cells, Cell Growth Differ. 6:691-698.
42. Janicke, R. U., X. Y. Lin, F. H. Lee, and A. G. Porter. 1996. Cyclin D3 sensitizes tumor cells to tumor necrosis factor induced, c-myc-dependent apoptosis. Mol. Cell Biol. 16:5245-5253.
43. Rogatsky, L. J. M. Trowbridge, and M. J. Garabedian. 1997. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific, transeriptional regulatory mechanisms. Mol. Cell Biol. 17:3181-3193.
44. Johnson, M. 1995. The anti inflammatory profile of fluticasone propionate. Allergy 50:11-14.
45. Barnes, P. J., and S. Pedersen. 1993. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am. Rev. Respir. Dis. 148(Suppl.):S1-S26.
46. z-adrenoceptor stimulation. Br. J. Pharmacol. 121:361-368.
47. Panettieri, R. A., R. K. Murray, L. R. DePalo, P. A. Yadvish, and M. I. Kollikoff. 1989. A human airway smooth muscle cell line that retains physiological responsivencss. Am. J. Physiol. 256:C329-C335.
48. Tomlinson, P. R., J. W Wilson, and A. G. Stewart. 1994. Inhibition by salbulamol of the proliferation of human airway smooth muscle cells grown in culture. Br. J. Pharmacol, 111:641-647.
49. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1905. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686-7689.
50. Alessi, D. R., A. Cuenda. P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
51. Oliver, M. H., N. K. Harrison, J. E. Bishop. P. J. Cole. and G. J. Laurent. 1989. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J. Cell Sci. 92:513-518.
52. Xiong. Y., T, Conolly, B. Futcher, and D. Beach. 1991. Human D-type cyclin. Cell 65:691-699.
53. Nudel. U., R. Zakut. M. Shani, S. Neumnn, Z. Levy, and D. Yaffe. 1983. The nucleotide sequence of the rat cytoplasmic beta-actin gene. Nucl. Acids Res. 11:1759-1771.
54. Moguilewsky, M., and O. Philibert. 1984. Potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J. Steroid Biochem. 20:271-276.
55. Nordeen. S. K., B. J. Bona, and M. L. Moyer. 1993. Latent agonist activity of the steroid antagonist, RU4R6, is unmasked in cells treated with activators of protein kinase A. Mol. Endocrinol. 7:731-742.
56. Jackson, T. A., J. K. Richer, D. L. Bain, G. S. Takimoto, L. Tung, and K. B. Horwitz. 1997. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/ SPA and the corcpressors N-CoR or SMRT. Mol. Endocrinol. 11:693-705.
57. Barlek, J., J. Bartkova, and J. Lukas. 1996, The retinoblastoma protein pathway and the restriction point. Curr, Opin. Cell Biol. 8:805-814.
58. Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J. Y, Kato. 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Biol. 14:2066-2076.
59. Reisman, D., and E. A. Thompson. 1995, Glucocorticoid regulationof cyclin D3 gene transcription and mRNA stability in lymphoid cells. Mol. Endocrinol. 9:1500-1509.
60. ′ untranslated region mediate the increased turnover of interferon mRNA induced by glucocorticoids. J. Exp. Med. 173:349-355.
61. Fabbri, L, P. S. Burge, L. Croonenborgh, F. Warlies, B. Wecke, A, Ciaccia, and C. Parker, 1993. Comparison of fluticasone propionate with bectomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax 48:817-823.
62. Hogger, P., and P. Rohdewald. 1994. Binding kinetics of fluticasone propionale to the human glucocorticoid receptor. Steroids 59:597-602.
63. Hagan, J. B., H. Kita, and G. J. Gleich. 1998. Inhibition interluken-5 me diated eosinophil viability by fluticasone 17-propionate; comparison with other glucocorticoids, Clin. Exp. Allergy 28:999-1006.
64. Ray, K. P., S. Farrow, M. Daly, F. Talabot, and N. Searle, 1997. Induction of the F-selcctin promoter by inlerleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids. Biochem. J. 328:707-715.
65. Bornfeldt, K. E., J. S. Campbell, H. Koyama, G. M. Argast, C. C. Leslie, F. W. Raines, E. G. Krebs, and R. Ross. 1997. The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. J. Clin. Invest. 100:875-885.
66. Swantek, J. L., M. H. Cobb, and T. D. Geppert. 1997. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/ SAPK. Mol. Cell Biol. 17:6274-6282.
67. van der Saag. P. T., F. Caldenhoven, and A. van de Stolpe. 1996. Molecular mechanisms of steroid action: a novel type of cross-talk between glucocorticoids and NF-kappa B transcription factors. Eur. Respir. J. 22:146s-153s.
68. Pulverer, B. J., J. M. Kyriakis, J. Avruch, E. Nikolakaki, and J. R. Woodgelt. 1991, Phosphorylation of c-jun mediated by MAP kinases. Nature 353: 670-674.
69. Waskiewiez, A. J., and J. A. Cooper. 1995. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr. Opin. Cell Biol. 7:798-805.
70. Li, J., T. A. Johnson, L. A. Hanson, and D. G. Beer. 1996. Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells. Mol. Carcinog. 16:213-220.
71. Sikora, E., E. Grassili, E. Bellesta, L. Troiano, and C. Franceschi. 1993. Studies of the relationship between cell proliferation and cell death: III. AP-1 DNA binding activity during concanavalin A-induced proliferation or dexamethasone-induced apoptosis of rat thymocytes, Biochem. Biophys. Res. Commun. 192:386 391.
72. Phuchareon, J., and T. Tokuhisa. 1995. Deregulated c-Fos/AP-I modulates expression of the cyclin and the cdk gene in splenic B cells stimulated with lipopolysaecharide. Cancer Lett. 92:203-208.
73. Cato, A. C., H. Konig, H. Ponta, and P. Herrlich. 1992. Steroids and growth promoting factors in the regulation of expression of genes and gene networks. J. Steroid Biochem. Mol. Biol. 43:63-68.
74. Barnes, P. J., and S. Pedersen. 1993. Efficacy and safety of inhaled corticosteroids in asthma. Am. Rev. Respir. Dis. 148:81-826.
75. Rhee, K., VV. Bresnahan, A. Hirai, M. Hirai, and E. A. Thompson. 1995. c-Myc and cyclin D3 (CcnD3) genes arc independent targets for glucocorticoid inhibition of Iymphoid cell proliferation. Cancer Res. 55:418-195.
76. van Essen-Zandvliet, E. E., M. D. Hughes, H. J. Waalkens, E. J. Duiverman, S. J. Pocock, and K. F. Kerrebijn. 1992. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma: the Dutch Chronic Nonspecific Lung Disease Study Group. Am. Rev. Respir. Dis. 146:547-554.
77. Agertoft, L., and S. Pedersen. 1994. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 88:373-381.
78. Selroos, O., A. Pietinalho, A. B. Lofroos, and H. Riska. 1995. Effect of early vs late intervention with inhaled corticosteroids in asthma, Chest 108 1228-1234.
79. Olivieri, D., A. Chetta, M. DelDonno, G. Bertorelli, A. Casalini, A. Pecsi, R. Testi, and A. Foresi. 1997. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study, Am. J Respir, Crit. Care Med. 155:1864-1871.
80. Adcock, I. M., S. J. Lane, C. R. Brown. T. H. Lee, and P. J. Barnes. 1995. Abnormal glucocorticoid receptor-activator protein I interaction in steroid-resistant asthma. J. Exp. .Med. 182:1951-1958.